Search Results for “dealforma” – Page 3 – Endpoints News

SIGN UP

search results for: dealforma

Dealmaking spiked to record levels in April as Covid-19 triggered a fever of partnering. But what happens to ...

3 years ago

Who's doing deals in the midst of a crippling pandemic? Here are the top 10 players for March

3 years ago

The big C: The dealmakers, dollars and diseases that have transformed the Chinese biopharma market

3 years ago

The top 100 biopharma venture investors at the megabillions deal table

3 years ago

Biotech was big in 2019, but here's one record no one wanted to see broken: Most bankruptcies

3 years ago

Just how big is the biopharma dealmaking world? In 2019 we saw megabillions in cash change hands, and that's just the ...

3 years ago

Paul Biondi's track record at Bristol-Myers covered billions in deals of every shape and size. Here's the complete ...

3 years ago

The big drug hunters: Novartis’ $28B-plus deal spree makes Vas Narasimhan one of the top dealmakers of our time

3 years ago

How much has the cancer R&D frenzy translated into drug approvals? A lot

3 years ago

Vertex buys the top spot on the list of the biggest preclinical M&A deals. Were they robbed or was it a steal?

3 years ago

Worst. biotech. deal. ever? Turns out AbbVie has plenty of competition for that title

3 years ago

Bayer’s $240M upfront for BlueRock acquisition puts them in the high rollers club for preclinical biotech buyouts

3 years ago

Novartis' $18.5B in M&A under Vas Narasimhan says a lot about their careful — but opportunistic — deal strategy

3 years ago

H1 analysis: The high-stakes table in the biotech deals casino is paying out some record-setting winnings

3 years ago

The top 15 mega-deals in biopharma: AbbVie and Bristol-Myers acquisitions stir fresh debate over what's too big to ...

4 years ago

Gene therapy R&D deals turn red hot as Big Pharma steps up to play

4 years ago

Biopharma BD teams are speeding into the fast lane — cash in hand — as dealmaking continues to heat up in Q1 ...

4 years ago

Top 5 Chinese players: What does Everest's landmark deal with Immunomedics say about the flurry of in-licensing to ...

4 years ago

First page Previous page 1 234 Next page Last page

latest

Most read

15 leaders giving voice and visibility to the LGBTQ community in biopharma

5 days ago

GSK says its drug for chronic hep B could ‘lead to a functional cure’ — but will it be alone or in combination?

Yesterday

15 LGBTQ leaders in biopharma; Paul Stoffels’ Galapagos revamp; AstraZeneca catches up in ATTR; and more

Yesterday

Despite a slow start to the year for deals, PwC predicts a flurry of activity coming up

Yesterday

FDA unveils new draft guidance to help with oligonucleotide therapeutics development

Yesterday

see latest stream